{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:38:15Z","timestamp":1791005895516,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2019206614"],"award-info":[{"award-number":["H2019206614"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received anti-programmed cell death protein 1 (PD-1) (camrelizumab) therapy and the occurrence of sequential immune-related adverse events (irAEs). Although many irAEs have been reported, severe myositis caused by camrelizumab with simultaneous involvement of multiple organs, including the myocardium, respiratory muscles, and skeletal muscles, has rarely been described in literature. This 69-year-old male patient developed a grade 4 camrelizumab-induced adverse reaction according to the Common Terminology Criteria for Adverse Events (CTCAE) and was successfully treated with methylprednisolone and immunoglobulins. The early identification of irAEs, immediate discontinuation of immunotherapy, use of steroids and\/or immunosuppressants, and adjuvant supportive treatment are critical to the clinical prognosis of patients. It should be aware that autoimmune complications can occur even when ICI treatment is ceased.<\/jats:p>","DOI":"10.3389\/fonc.2021.778185","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:51:25Z","timestamp":1641171085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review"],"prefix":"10.3389","volume":"11","author":[{"given":"Jing","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peidan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer Statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.13220\/j.cnki.jipr.2015.02.003","article-title":"Pd-1\/Pd-Ll Signaling Pathway and Its Application in Tumor","volume":"42","author":"Wang","year":"2015","journal-title":"J Int Pharm Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated With Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for Immune-Related Myocarditis Due to Pd-1 Therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-Induced Myasthenia Gravis: A Fatal Case Report","volume":"24","author":"March","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0172","article-title":"Reactive Capillary Hemangiomas: A Novel Dermatologic Toxicity Following Anti-Pd-1 Treatment With Shr-1210","volume":"16","author":"Chen","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (Shr-1210) Alone or in Combination With Gemcitabine Plus Cisplatin for Nasopharyngeal Carcinoma: Results From Two Single-Arm, Phase 1 Trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, Activity, and Biomarkers of Shr-1210, an Anti-Pd-1 Antibody, for Patients With Advanced Esophageal Carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, Anti-Tumour Activity, and Pharmacokinetics of Fixed-Dose Shr-1210, an Anti-Pd-1 Antibody in Advanced Solid Tumours: A Dose-Escalation, Phase 1 Study","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"Pd-1 and Pd-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis With Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/cco.2020.03.08","article-title":"A Retrospective Study of Immune Checkpoint Inhibitor-Associated Myocarditis in a Single Center in China","volume":"9","author":"Wang","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab Versus Investigator\u2019s Choice of Chemotherapy as Second-Line Therapy for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (Escort): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab Versus Placebo in Resected Stage Iii Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.02.024","article-title":"Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis","volume":"12","author":"Tan","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-Related Myasthenia Gravis With Myositis and Myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.38282","article-title":"Drug-Associated Polymyalgia Rheumatica\/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of Ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000178","article-title":"Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases","volume":"40","author":"Pushkarevskaya","year":"2017","journal-title":"J Immunother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","article-title":"Progressive Hypoventilation Due to Mixed Cd8(+) and Cd4(+) Lymphocytic Polymyositis Following Tremelimumab - Durvalumab Treatment","volume":"5","author":"John","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-2620","article-title":"Myocarditis Related to Immune Checkpoint Inhibitors Treatment: Two Case Reports and Literature Review","volume":"10","author":"Chen","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and Neuromuscular Side-Effects Induced by Immune Checkpoint Inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"Intenational Consensus Guidance for Management of Myasthenia Gravis: Executive Summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of Myasthenia Gravis in a Patient With Melanoma Treated With Pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25055","article-title":"Myasthenia Gravis Exacerbation Associated With Pembrolizumab","volume":"54","author":"Zhu","year":"2016","journal-title":"Muscle Nerve"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine Receptor Binding Antibody-Associated Myasthenia Gravis and Rhabdomyolysis Induced by Nivolumab in a Patient With Melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.778185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:51:30Z","timestamp":1641171090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.778185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":31,"alternative-id":["10.3389\/fonc.2021.778185"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.778185","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"article-number":"778185"}}